DAUNEON is an anticancer drug that blocks DNA synthesis in tumor cells, slowing their growth and contributing to the destruction of cancer cells. It is used in chemotherapy for the treatment of acute leukemias and other tumors, including breast, lung, head, and neck cancers. The drug is effective in combination therapy to reduce tumor size and prevent its spread.
The product is used for:
Acute myeloblastic leukemia
Acute lymphoblastic leukemia
Breast cancer
Lung, head, and neck cancers
Other solid tumors
DAUNEON is administered intravenously, typically in a hospital setting. The dosage and duration of treatment are determined individually, depending on the type of tumor, disease stage, and patient response. The drug is administered through an infusion or injection, and treatment is carried out in cycles in combination with other anticancer agents.
Contraindications:
Hypersensitivity to doxorubicin or other components of the product
Severe liver and kidney diseases
Pregnancy and breastfeeding (under medical supervision)
Severe active infections
Side Effects:
Nausea, vomiting
Headache, dizziness
Leukopenia and thrombocytopenia
Loss of appetite, fatigue
Allergic reactions (rash, itching)
